Eli Lilly

Safe-Biopharma launches cyber security consulting service for life science, healthcare

Friday, April 24, 2015 01:18 PM

SAFE-BioPharma Association has created SBP Digital Trust Consulting, a resource of internationally recognized identity and access management (IAM) policy and technical experts for life science and healthcare companies seeking to develop improved cyber security strategies.

More... »

Quest Diagnostics

WCG encourages its global research network to use ACTA as clinical trial contract solution

Monday, April 20, 2015 06:00 AM

Global IRB WIRB-Copernicus Group (WCG) today said it will encourage the 1,200 members of its global research network to accept and use the Accelerated Clinical Trial Agreement (ACTA) as their default agreement for industry-sponsored, multicenter clinical trials.

More... »


Incyte joins Safe-Biopharma Association

Friday, April 17, 2015 12:39 PM

Incyte, a Delaware-based biopharmaceutical company, has joined SAFE-BioPharma Association, a nonprofit industry coalition responsible for the ongoing development and implementation of the SAFE-BioPharma digital identity and signature standard.

More... »

Takeda appoints new president of U.S. business unit

Thursday, April 16, 2015 03:11 PM

Takeda Pharmaceutical has appointed Ramona Sequeira as president of the U.S. business unit. In this role, Sequeira will lead all business operations for the U.S., and will report to Christophe Weber, the president and CEO of Takeda.

More... »

Eli Lilly inks deals with Innovent Biologics, Hanmi Pharmaceutical

Friday, March 20, 2015 02:20 PM

Eli Lilly and Innovent Biologics, a biopharmaceutical company in China, have inked a biotech drug development collaboration to collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade. The agreement creates possible new treatment options for cancer patients, while strengthening the presence of both companies in the Chinese oncology market.

More... »

$100M invested in new Dementia Discovery fund

Wednesday, March 18, 2015 01:11 PM

The U.K. government has announced over $100 million will be invested in a pioneering new global Dementia Discovery Fund. Major pharmaceutical companies Biogen Idec, GlaxoSmithKline, Johnson & JohnsonEli Lilly and Pfizer have all committed in principle to investing in the project, alongside Alzheimer's Research U.K. and the U.K. government.

More... »

NIH-led effort launches Big Data portal for Alzheimer’s drug discovery

Friday, March 6, 2015 12:16 PM

A NIH-led public-private partnership to transform and accelerate drug development has launched a new Alzheimer’s Big Data portal—including delivery of the first wave of data—for use by the research community. The new data sharing and analysis resource is part of the Accelerating Medicines Partnership (AMP), an unprecedented venture bringing together NIH, FDA, industry and academic scientists from a variety of disciplines to translate knowledge faster and more successfully into new therapies.

More... »

Denovo Biopharma licenses late-stage neuroscience drug from Eli Lilly

Wednesday, March 4, 2015 01:15 PM

Denovo Biopharma, a privately held biotechnology company based in San Diego, has exclusively licensed Pomaglumetad Methionil (mGlu2/3 receptor agonist), a late-stage neuroscience drug, from Eli Lilly. Denovo gains all rights to develop, manufacture and commercialize pomaglumetad globally, including transfer of all intellectual property and other rights, data and information. Lilly has an option to re-acquire pomaglumetad upon a successful clinical trial, for predetermined undisclosed financial terms.

More... »

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015 03:03 PM

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis' global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

More... »

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015 12:20 PM

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

More... »


CWWeekly

April 27

Doctors, patients in the U.S. and U.K. agree: Mobile health apps are good for our health

AARP teams with Georgia Tech's HomeLab, Pfizer and UnitedHealthcare to test wearables with consumers 50+

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs